Results 11 to 20 of about 1,512,475 (325)
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination
American journal of hematology/oncology, 2021 Cases of apparent secondary immune thrombocytopenia (ITP) after SARS-CoV-2 vaccination with both the Pfizer and Moderna versions have been reported and reached public attention.Eun-Ju Lee, D. Cines, T. Gernsheimer, C. Kessler, M. Michel, M. Tarantino, J. Semple, D. Arnold, B. Godeau, Michele P. Lambert, J. Bussel +10 moresemanticscholar +1 more sourceThe Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
MMWR. Morbidity and mortality weekly report, 2021 On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA ...Sara E. Oliver, Julia W. Gargano, M. Marin, Megan Wallace, K. Curran, M. Chamberland, Nancy McClung, D. Campos-Outcalt, Rebecca L Morgan, Sarah A Mbaeyi, J. Romero, H. Talbot, Grace M. Lee, B. Bell, K. Dooling +14 moresemanticscholar +1 more sourceSafety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis
Nature Communications, 2023 Despite vaccine availability, influenza remains a substantial global public health concern. Here, we report interim findings on the primary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of a quadrivalent messenger RNA Ivan T. Lee, Raffael Nachbagauer, David Ensz, Howard Schwartz, Lizbeth Carmona, Kristi Schaefers, Andrei Avanesov, Daniel Stadlbauer, Carole Henry, Ren Chen, Wenmei Huang, Daniela Ramirez Schrempp, Jintanat Ananworanich, Robert Paris +13 moredoaj +1 more sourceEffectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
MMWR. Morbidity and mortality weekly report, 2021 Nursing home and long-term care facility residents live in congregate settings and are often elderly and frail, putting them at high risk for infection with SARS-CoV-2, the virus that causes COVID-19, and severe COVID-19-associated outcomes; therefore ...S. Nanduri, T. Pilishvili, Gordana Derado, M. Soe, Philip Dollard, Hsiu Wu, Qunna Li, S. Bagchi, Heather Dubendris, R. Link-Gelles, J. Jernigan, D. Budnitz, Jeneita M. Bell, A. Benin, N. Shang, J. Edwards, J. Verani, S. Schrag +17 moresemanticscholar +1 more sourceEffectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021
MMWR. Morbidity and mortality weekly report, 2021 Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3).M. Tenforde, Samantha M. Olson, W. Self, H. Talbot, C. Lindsell, J. Steingrub, N. Shapiro, A. Ginde, D. Douin, M. Prekker, Samuel M. Brown, I. Peltan, M. Gong, A. Mohamed, Akram Khan, M. Exline, D. Files, K. Gibbs, William B. Stubblefield, J. Casey, T. Rice, Carlos G. Grijalva, D. Hager, A. Shehu, N. Qadir, Steven Y. Chang, Jennifer G. Wilson, M. Gaglani, Kempapura Murthy, Nicole Calhoun, A. Monto, E. Martin, A. Malani, R. Zimmerman, F. Silveira, D. Middleton, Yuwei Zhu, Dayna Wyatt, Meagan Stephenson, A. Baughman, K. Womack, K. Hart, Miwako Kobayashi, J. Verani, Manish M Patel +44 moresemanticscholar +1 more sourceSustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.
MMWR. Morbidity and mortality weekly report, 2021 Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals M. Tenforde, W. Self, Eric A. Naioti, A. Ginde, D. Douin, Samantha M. Olson, H. Talbot, J. Casey, N. Mohr, A. Zepeski, M. Gaglani, T. McNeal, S. Ghamande, N. Shapiro, K. Gibbs, D. Files, D. Hager, A. Shehu, M. Prekker, H. Erickson, M. Gong, A. Mohamed, D. Henning, J. Steingrub, I. Peltan, Samuel M. Brown, E. Martin, A. Monto, Akram Khan, C. Hough, L. Busse, C. T. ten Lohuis, A. Duggal, Jennifer G. Wilson, A. Gordon, N. Qadir, Steven Y. Chang, C. Mallow, C. Rivas, H. Babcock, Jennie H. Kwon, M. Exline, N. Halasa, J. Chappell, A. Lauring, Carlos G. Grijalva, T. Rice, I. D. Jones, William B. Stubblefield, A. Baughman, K. Womack, C. Lindsell, K. Hart, Yuwei Zhu, Meagan Stephenson, S. Schrag, Miwako Kobayashi, J. Verani, Manish M. Patel, Nicole Calhoun, Kempapura Murthy, Judy Herrick, A. McKillop, E. Hoffman, Martha Zayed, Michael E. Smith, Natalie Settele, J. Ettlinger, E. Priest, Jennifer Thomas, A. Arroliga, M. Beeram, R. Kindle, Lori-Ann Kozikowski, Lesley De Souza, Scott Ouellette, Sherell Thornton-Thompson, P. Tyler, Omar Mehkri, K. Ashok, Susan Gole, Alexander King, Bryan Poynter, Nicholas Stanley, Audrey Hendrickson, Ellen Maruggi, Tyler Scharber, J. Jorgensen, R. Bowers, J. King, V. Aston, Brent P. Armbruster, R. Rothman, Rahul R. Nair, J. Chen, S. Karow, E. Robart, P. Maldonado, Maryiam Khan, Preston So, Joel D. Levitt, Cynthia Perez, A. Visweswaran, J. Roque, Adreanne Rivera, Trevor Frankel, Michelle P Howell, Jennifer Friedel, Jennifer Goff, D. Huynh, Michael Tozier, C. Driver, Michael Carricato, Alexandra E Foster, Paul Nassar, Laura Stout, Zita A. Sibenaller, Alicia Walter, J. Marés, Logan Olson, Bradley Clinansmith, C. Rivas, H. Gershengorn, E. McSpadden, R. Truscon, A. Kaniclides, Lara J. Thomas, Ramsay Bielak, W. Valvano, Rebecca Fong, W. Fitzsimmons, C. Blair, A. Valesano, Julie Gilbert, Christine D. Crider, Kyle A. Steinbock, Thomas C. Paulson, Layla A. Anderson, Christina Kampe, Jake Johnson, Rendie Mchenry, Marcia A. Blair, D. Conway, M. LaRose, Leigha D. Landreth, Madeline Hicks, L. Parks, Jahnavi Bongu, David W. Mcdonald, Candice Cass, Sondra M. Seiler, David Park, T. Hink, Meghan A. Wallace, C. Burnham, Olivia G. Arter +155 moresemanticscholar +1 more sourceSelective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein
Nature Communications, 2022 IL-2 has been used to expand regulatory T (Treg) cells for treating inflammatory disorders. Here the authors test an engineered IL-2 mutein, delivered subcutaneously as mRNA, to show its increased specificity for activating and expanding Treg cells in ...Seymour de Picciotto, Nicholas DeVita, Chiaowen Joyce Hsiao, Christopher Honan, Sze-Wah Tse, Mychael Nguyen, Joseph D. Ferrari, Wei Zheng, Brian T. Wipke, Eric Huang +9 moredoaj +1 more sourceUse of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
MMWR. Morbidity and mortality weekly report, 2021 In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines, and in February 2021, FDA issued an EUA for the Janssen (Johnson & Johnson) COVID-19 vaccine.Hannah G. Rosenblum, S. Hadler, Danielle L. Moulia, T. Shimabukuro, John R. Su, N. Tepper, K. Ess, E. Woo, A. Mba-Jonas, M. Alimchandani, N. Nair, N. Klein, K. Hanson, L. Markowitz, M. Wharton, V. McNally, J. Romero, H. Talbot, Grace M. Lee, M. Daley, Sarah A Mbaeyi, Sara E. Oliver +21 moresemanticscholar +1 more sourceHealth disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract
The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.Ani Kardashian, Marina Serper, Norah Terrault, Lauren D. Nephew +3 morewiley +1 more sourceTherapeutic enzyme engineering using a generative neural network
Scientific Reports, 2022 Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and ...Andrew Giessel, Athanasios Dousis, Kanchana Ravichandran, Kevin Smith, Sreyoshi Sur, Iain McFadyen, Wei Zheng, Stuart Licht +7 moredoaj +1 more source
